ARIDOL KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ARIDOL KIT (ARIDOL KIT).
Mannitol, a sugar alcohol, acts as an osmotic diuretic and osmotic agent. It increases plasma osmolality, drawing water from tissues into the bloodstream and enhancing urinary excretion. In the respiratory tract, it is used as a bronchial challenge agent to induce bronchoconstriction in patients with asthma by increasing airway osmolality and triggering mast cell mediator release.
| Metabolism | Mannitol is not significantly metabolized; it is primarily excreted unchanged in urine. A small amount may be metabolized in the liver to glycogen or oxidized to carbon dioxide. |
| Excretion | Mannitol (the active ingredient in Aridol Kit) is primarily excreted unchanged in the urine via glomerular filtration, with approximately 80-90% of an intravenous dose eliminated within 24 hours. Less than 10% is metabolized in the liver, and negligible amounts are eliminated in feces or bile. |
| Half-life | The terminal elimination half-life of mannitol is approximately 100 minutes (1.7 hours) in patients with normal renal function. This may be prolonged up to 36 hours in patients with renal impairment, necessitating dose adjustment. |
| Protein binding | Mannitol exhibits negligible protein binding (< 1%) and does not significantly bind to plasma proteins such as albumin. |
| Volume of Distribution | The volume of distribution (Vd) of mannitol is approximately 0.5 L/kg in adults. This value approximates total body water, consistent with its distribution primarily into extracellular fluid. |
| Bioavailability | Mannitol is not significantly absorbed after oral administration due to its high polarity; oral bioavailability is less than 5%. The route of administration for Aridol Kit is inhalation (as a bronchial challenge test), where systemic bioavailability is minimal but variable, typically less than 10% of the inhaled dose. |
| Onset of Action | Diuresis occurs within 1-3 minutes following intravenous administration of mannitol. The onset of osmotic diuresis is rapid, corresponding to the time required for distribution to the kidneys. |
| Duration of Action | The duration of diuretic effect is approximately 1-3 hours after intravenous infusion, depending on dose and renal function. The effect typically ends when mannitol clearance by the kidneys is complete, which parallels its half-life. |
Aridol (mannitol) is administered via inhalation as a dry powder for bronchial challenge testing. The standard adult dose is a single capsule (25 mg) inhaled using the Aridol inhaler device, with doses escalated as per protocol (e.g., 5, 10, 20, 40 mg cumulative) until a 15% fall in FEV1 is achieved or maximum cumulative dose of 160 mg is reached.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required for renal impairment as mannitol is minimally absorbed after inhalation and systemic exposure is negligible. |
| Liver impairment | No dose adjustment required for hepatic impairment as mannitol is not metabolized by the liver and pharmacokinetics are not altered in hepatic dysfunction. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use is not recommended in children under 18 years of age. |
| Geriatric use | No specific dose adjustments are recommended for elderly patients; however, consider age-related decline in pulmonary function and potential comorbidities. Use with caution per standard testing protocols. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ARIDOL KIT (ARIDOL KIT).
| Breastfeeding | Mannitol is known to be excreted in human milk following intravenous administration. After inhalation, systemic absorption is minimal, and breast milk levels are expected to be negligible. The M/P ratio is unknown. Caution is advised, but risk to nursing infant is likely low. Consider temporary cessation of breastfeeding for 24 hours after procedure if concerned. |
| Teratogenic Risk | Aridol (mannitol) is a diagnostic agent with negligible systemic absorption following inhalation. No fetal risks are established due to lack of placental transfer. However, no controlled human studies exist. In animal studies, no teratogenic effects were observed at doses up to 10 times the human dose. Risk cannot be completely excluded, but is considered minimal across all trimesters. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Known hypersensitivity to mannitol or any component of the kit.","Severe asthma (FEV1 < 50% predicted or current asthma exacerbation).","Unstable asthma or recent respiratory infection.","Pulmonary hypertension or other cardiovascular conditions requiring caution."]
| Precautions | ["Risk of severe bronchospasm: Use only in controlled settings with resuscitation equipment available.","Contraindicated in patients with severe asthma or FEV1 < 50% predicted.","May cause acute bronchoconstriction; monitor FEV1 closely during testing.","Not for treatment or relief of asthma symptoms."] |
| Food/Dietary | No specific food interactions with Aridol Kit. However, avoid foods high in caffeine (coffee, tea, chocolate) for at least 6 hours before the test as caffeine can affect bronchial reactivity. |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is required during Aridol challenge testing. Standard precautions for bronchial challenge testing apply, including pulse oximetry and spirometry to detect bronchospasm. In pregnant women, consider fetal monitoring if bronchospasm occurs and oxygen saturation decreases; otherwise, monitoring is based on clinical condition. |
| Fertility Effects | No known effects on fertility. Animal studies have not shown impairment of fertility at doses up to 10 times the human dose. Inhalation route minimizes systemic exposure, making significant fertility effects unlikely. |
| Clinical Pearls | Aridol (mannitol) is a bronchial provocation test used to diagnose asthma. It should be administered via inhalation only. Patients must have baseline FEV1 ≥70% predicted. Monitor FEV1 at 30, 60, 90, and 120 seconds after each dose. A fall in FEV1 of ≥15% from baseline at two consecutive time points indicates a positive response. Have rescue bronchodilator (e.g., albuterol) available. Do not perform if patient has had respiratory infection within 4 weeks or has severe hypertension. |
| Patient Advice | This test checks for airway hyperresponsiveness, which is common in asthma. · You will inhale increasing doses of a dry powder through a device. · Do not take short-acting bronchodilators for 8 hours, long-acting for 24 hours, or leukotriene modifiers for 48 hours before the test. · Avoid caffeine, tobacco, and exercise for at least 6 hours prior to the test. · You may experience coughing, wheezing, or shortness of breath during the test; inform the clinician immediately. · After the test, stay for observation until your breathing returns to normal. |